Payment overview · 2025
General Payments
$411.20
22 reported records · 13 companies
Healthcare provider profile · identity verified
Claude H Meeks, MD
Allopathic & Osteopathic Physicians|Family Medicine · ABBEVILLE, LA · NPI 1154539518
Verified facts
What the public records show
CMS Open Payments records show Claude H Meeks, MD received $411.20 in general payments during 2025 across 22 reported records.
Axsome Therapeutics, Inc. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $71.14 | 17.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.25 | 11.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.17 | 11.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.65 | 10.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.20 | 9.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.28 | 8.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.42 | 5.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.90 | 5.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.51 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.22 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.91 | 4.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.01 | 4.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.54 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $411.20 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $71.14 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.17 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
74 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
139 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 579 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 525 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 117 |
| Gabapentin | Gabapentin | 335 | 108 |
| Metformin Hcl | Metformin Hcl | 297 | 100 |
| Omeprazole | Omeprazole | 267 | 92 |
| Ezetimibe | Ezetimibe | 240 | 86 |
| Meloxicam | Meloxicam | 240 | 101 |
| Clonidine Hcl | Clonidine Hcl | 224 | 101 |
| Losartan Potassium | Losartan Potassium | 219 | 72 |
| Montelukast Sodium | Montelukast Sodium | 202 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 73 |
| Trazodone Hcl | Trazodone Hcl | 190 | 54 |
| Furosemide | Furosemide | 189 | 62 |
| Tramadol Hcl | Tramadol Hcl | 185 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 178 | 80 |
| Fluticasone Propionate | Fluticasone Propionate | 176 | 106 |
| Lisinopril | Lisinopril | 172 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 53 |
| Allopurinol | Allopurinol | 157 | 56 |
| Pregabalin | Pregabalin | 156 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 64 |
| Trulicity | Dulaglutide | 139 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 40 |
| Alendronate Sodium | Alendronate Sodium | 126 | 39 |
| Alprazolam | Alprazolam | 123 | 37 |
| Potassium Chloride | Potassium Chloride | 119 | 53 |
| Sertraline Hcl | Sertraline Hcl | 111 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 30 |
| Baclofen | Baclofen | 102 | 36 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 101 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 29 |
| Simvastatin | Simvastatin | 94 | 30 |
| Prednisone | Prednisone | 84 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 27 |
| Mupirocin | Mupirocin | 80 | 48 |
| Valsartan | Valsartan | 80 | 32 |
| Linzess | Linaclotide | 74 | 27 |
| Carvedilol | Carvedilol | 72 | 18 |
| Farxiga | Dapagliflozin Propanediol | 72 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 23 |
| Mounjaro | Tirzepatide | 70 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 22 |
| Glimepiride | Glimepiride | 61 | 20 |
| Ozempic | Semaglutide | 61 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 57 |
| Mirtazapine | Mirtazapine | 59 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 18 |
| Levetiracetam | Levetiracetam | 55 | 15 |
| Azithromycin | Azithromycin | 53 | 45 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Glipizide | Glipizide | 53 | 23 |
| Celecoxib | Celecoxib | 52 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 38 |
| Eliquis | Apixaban | 51 | 18 |
| Jardiance | Empagliflozin | 51 | 19 |
| Enalapril Maleate | Enalapril Maleate | 50 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 23 |
| Buspirone Hcl | Buspirone Hcl | 46 | 20 |
| Fluconazole | Fluconazole | 45 | 31 |
| Januvia | Sitagliptin Phosphate | 45 | 12 |
| Donepezil Hcl | Donepezil Hcl | 44 | 15 |
| Methocarbamol | Methocarbamol | 44 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 43 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Ondansetron Odt | Ondansetron | 39 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Nystatin | Nystatin | 35 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 14 |
| Diazepam | Diazepam | 34 | suppressed |
| Famotidine | Famotidine | 34 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Amoxicillin | Amoxicillin | 32 | 28 |
| Glipizide Er | Glipizide | 32 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 17 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 30 |
| Lorazepam | Lorazepam | 29 | 15 |
| Methylprednisolone | Methylprednisolone | 29 | 26 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 24 |
| Atenolol | Atenolol | 24 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 11 |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | 11 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | 11 |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Alyacen | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Tri-Lo-Estarylla | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | 12 |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $411.20 · 22 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, CAPLYTA, IBSRELA, JARDIANCE, Korlym, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error